A phase Ib study of Oraxol (oral paclitaxel and encequidar) in patients with advanced malignancies

ConclusionThe oral administration of encequidar with paclitaxel was safe, achieved clinically relevant paclitaxel levels, and showed evidence of anti-tumor activity.

http://link.springer.com/10.1007/s00280-022-04443-1

Source: Cancer Chemotherapy and Pharmacology - June 22, 2022 Category: Cancer & Oncology Source Type: research